BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule AgonistFont size: A | A | A
2:38 AM ET 7/23/18 | PR Newswire
RELATED QUOTES
SAN DIEGO, July 23, 2018 /PRNewswire/ --
Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity. Regen has methodically optimized small molecules that bind to, and activate, the NR2F6 nuclear receptor.
"We are very pleased that we did not see any clinical signs of toxicity at any single dose of RG-NAE005 up to 2,000 mg/kg and did not see any toxicity at repeated doses of 400 mg/kg," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. He also adds, "This is very exciting, as it indicates that the drug will likely be safe in animals as we begin efficacy testing."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists of NR2F6 that should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity, as well as identifying antagonists in an effort to unleash the cancer-killing potential of a patient's own immune system.
"Drug safety is always the number one concern of any drug development process," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We are very pleased to see that this drug is safe in mice. It is another major milestone we have passed with this drug."
News 
Market Data 
Discover 
